Loading...
In October 2025, the U.S. Food and Drug Administration approved elinzanetant (Lynkuet) for the treatment of moderate-to-severe vasomotor symptoms of menopause. It is the second neurokinin antagonist approved by the FDA for this indication — along with fezolinetant (Veozah) — and has favorable effects on sleep, sweating, and vasodilation.
Elinzanetant’s approval was based on three industry-sponsored trials (OASIS 1–3) in which postmenopausal women ages 40 to 65 with moderate-to-severe vasomotor menopausal syndrome were randomized to daily oral elinzanetant (120 mg) or placebo. The three trials were consistent in their findings:
Over 12 weeks, women receiving elinzanetant had significantly greater reductions in both the fr…